Biologic and therapeutic role of HER2 in cancer

[1]  D. Larsimont,et al.  Evaluation of HER-2/NEU Protein Expression in Breast Cancer by Immunohistochemistry: An Interlaboratory Study Assessing the Reproducibility of HER-2/NEU Testing , 2002, Breast Cancer Research and Treatment.

[2]  O. Nanni,et al.  Prognostic significance of biologic markers in node-negative breast cancer patients: a prospective study , 2000, Breast Cancer Research and Treatment.

[3]  M. Colombo,et al.  Immunotherapy I: Cyclosine gene transfer strategies , 1996, Cancer and Metastasis Reviews.

[4]  F. Kern,et al.  MCF-7 breast cancer cells overexpressing transfectedc-erbB-2 have anin vitro growth advantage in estrogen-depleted conditions and reduced estrogen-dependence and tamoxifen-sensitivityin vivo , 1995, Breast Cancer Research and Treatment.

[5]  A. Ullrich,et al.  Monoclonal antibody therapy of human cancer: Taking the HER2 protooncogene to the clinic , 1991, Journal of Clinical Immunology.

[6]  S. Eccles,et al.  Differential modulation of proliferation, matrix metalloproteinase expression and invasion of human head and neck squamous carcinoma cells by c-erbB ligands , 2004, Clinical & Experimental Metastasis.

[7]  M. Campiglio,et al.  Role of proliferation in HER2 status predicted response to doxorubicin , 2003, International journal of cancer.

[8]  S. Ménard,et al.  HER2 overexpression and doxorubicin in adjuvant chemotherapy for resectable breast cancer. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  Gottfried Konecny,et al.  Quantitative association between HER-2/neu and steroid hormone receptors in hormone receptor-positive primary breast cancer. , 2003, Journal of the National Cancer Institute.

[10]  Barbara L. Smith,et al.  Preoperative therapy with trastuzumab and paclitaxel followed by sequential adjuvant doxorubicin/cyclophosphamide for HER2 overexpressing stage II or III breast cancer: a pilot study. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  H. Kato,et al.  Correlation between encoded protein overexpression and copy number of the HER2 gene with survival in non‐small cell lung cancer , 2003, International journal of cancer.

[12]  P. Ohashi,et al.  Making and breaking tolerance. , 2002, Current opinion in immunology.

[13]  S. Ménard,et al.  Prevention of spontaneous mammary adenocarcinoma in HER‐2/neu transgenic mice by foreign DNA , 2002, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[14]  Thomas Dittmar,et al.  Induction of cancer cell migration by epidermal growth factor is initiated by specific phosphorylation of tyrosine 1248 of c‐erbB‐2 receptor via epidermal growth factor receptor , 2002, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[15]  J. Trapani,et al.  Single-chain antigen recognition receptors that costimulate potent rejection of established experimental tumors. , 2002, Blood.

[16]  M. Bui,et al.  Prognostic and predictive value of HER2/neu oncogene in breast cancer , 2002, Microscopy research and technique.

[17]  Jayanta Debnath,et al.  The Role of Apoptosis in Creating and Maintaining Luminal Space within Normal and Oncogene-Expressing Mammary Acini , 2002, Cell.

[18]  Anthony Rhodes,et al.  Evaluation of HER-2/neu immunohistochemical assay sensitivity and scoring on formalin-fixed and paraffin-processed cell lines and breast tumors: a comparative study involving results from laboratories in 21 countries. , 2002, American journal of clinical pathology.

[19]  K. Miller,et al.  HER-2/neu expression in germ cell tumours , 2002, Journal of clinical pathology.

[20]  M. Wolter,et al.  Gene amplification and protein overexpression of c-erb-b2 in Barrett carcinoma and its precursor lesions. , 2002, American journal of clinical pathology.

[21]  N. Tsavaris,et al.  Immune changes in patients with advanced breast cancer undergoing chemotherapy with taxanes , 2002, British Journal of Cancer.

[22]  Guido Forni,et al.  Antitumor vaccines: is it possible to prevent a tumor? , 2002, Cancer Immunology, Immunotherapy.

[23]  Peter A Kaufman,et al.  Concordance between local and central laboratory HER2 testing in the breast intergroup trial N9831. , 2002, Journal of the National Cancer Institute.

[24]  Greg Yothers,et al.  Real-world performance of HER2 testing--National Surgical Adjuvant Breast and Bowel Project experience. , 2002, Journal of the National Cancer Institute.

[25]  Hermann Herbst,et al.  Common Adult Stem Cells in the Human Breast Give Rise to Glandular and Myoepithelial Cell Lineages: A New Cell Biological Concept , 2002, Laboratory Investigation.

[26]  M. Cheever,et al.  Generation of T-cell immunity to the HER-2/neu protein after active immunization with HER-2/neu peptide-based vaccines. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[27]  F. Hirsch,et al.  Evaluation of HER-2/neu gene amplification and protein expression in non-small cell lung carcinomas , 2002, British Journal of Cancer.

[28]  R. Epstein,et al.  Dominant negative knockout of p53 abolishes ErbB2-dependent apoptosis and permits growth acceleration in human breast cancer cells , 2002, British Journal of Cancer.

[29]  G. Forni,et al.  Prophylactic cancer vaccines. , 2002, Current opinion in immunology.

[30]  D. Jäger,et al.  Clinical cancer vaccine trials. , 2002, Current opinion in immunology.

[31]  Lei Xu,et al.  Tumour biology: Herceptin acts as an anti-angiogenic cocktail , 2002, Nature.

[32]  F. Hirsch,et al.  Epidermal growth factor receptor family in lung cancer and premalignancy. , 2002, Seminars in oncology.

[33]  Yudong D. He,et al.  Gene expression profiling predicts clinical outcome of breast cancer , 2002, Nature.

[34]  Y. Zeng,et al.  Absence of evidence for HER2 amplification in nasopharyngeal carcinoma. , 2002, Cancer genetics and cytogenetics.

[35]  J. Feldner,et al.  Cancer cell motility--on the road from c-erbB-2 receptor steered signaling to actin reorganization. , 2002, Experimental cell research.

[36]  J. Bartlett,et al.  Gene amplification and overexpression of HER2 in renal cell carcinoma , 2002, BJU international.

[37]  A Choudhury,et al.  Cellular immunity to the Her-2/neu protooncogene. , 2002, Advances in cancer research.

[38]  S. Ménard,et al.  Erratum: Letter to the editor (Breast Cancer Research and Treatment (2001) 70 (155-156)) , 2002 .

[39]  Piero Musiani,et al.  Combined Allogeneic Tumor Cell Vaccination and Systemic Interleukin 12 Prevents Mammary Carcinogenesis in HER-2/neu Transgenic Mice , 2001, The Journal of experimental medicine.

[40]  S. Ménard,et al.  HER2 as a Prognostic Factor in Breast Cancer , 2001, Oncology.

[41]  R. Tibshirani,et al.  Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[42]  Y. Yarden.  The EGFR family and its ligands in human cancer. signalling mechanisms and therapeutic opportunities. , 2001, European journal of cancer.

[43]  M. Bissell,et al.  ErbB2, but not ErbB1, reinitiates proliferation and induces luminal repopulation in epithelial acini , 2001, Nature Cell Biology.

[44]  S. Ménard,et al.  Role of p53 in HER2-induced Proliferation or Apoptosis* , 2001, The Journal of Biological Chemistry.

[45]  T. Fleming,et al.  Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. , 2001, The New England journal of medicine.

[46]  A. Ullrich,et al.  The epidermal growth factor receptor family as a central element for cellular signal transduction and diversification. , 2001, Endocrine-related cancer.

[47]  K. Knutson,et al.  Immunization with a HER-2/neu helper peptide vaccine generates HER-2/neu CD8 T-cell immunity in cancer patients. , 2001, The Journal of clinical investigation.

[48]  S. Ménard,et al.  Response to cyclophosphamide, methotrexate, and fluorouracil in lymph node-positive breast cancer according to HER2 overexpression and other tumor biologic variables. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[49]  M. Campiglio,et al.  HER2 overexpression in various tumor types, focussing on its relationship to the development of invasive breast cancer. , 2001, Annals of oncology : official journal of the European Society for Medical Oncology.

[50]  P. Stanton,et al.  The value of the human epidermal growth factor receptor-2 (HER2) as a prognostic marker. , 2001, European journal of cancer.

[51]  S. Ménard,et al.  Prevention of spontaneous neu-expressing mammary tumor development in mice transgenic for rat proto-neu by DNA vaccination , 2001, Gene Therapy.

[52]  Yosef Yarden,et al.  Molecular mechanisms underlying ErbB2/HER2 action in breast cancer , 2000, Oncogene.

[53]  Piero Musiani,et al.  DNA Vaccination Against Rat Her-2/Neu p185 More Effectively Inhibits Carcinogenesis Than Transplantable Carcinomas in Transgenic BALB/c Mice1 2 , 2000, The Journal of Immunology.

[54]  Christian A. Rees,et al.  Molecular portraits of human breast tumours , 2000, Nature.

[55]  H. Allgayer,et al.  c-erbB-2 is of independent prognostic relevance in gastric cancer and is associated with the expression of tumor-associated protease systems. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[56]  R. Kerbel,et al.  'Accidental' anti-angiogenic drugs. anti-oncogene directed signal transduction inhibitors and conventional chemotherapeutic agents as examples. , 2000, European journal of cancer.

[57]  A. Sacchi,et al.  Cooperative Signaling between α6β4Integrin and ErbB-2 Receptor Is Required to Promote Phosphatidylinositol 3-Kinase-dependent Invasion* , 2000, The Journal of Biological Chemistry.

[58]  R. Coppari,et al.  DNA vaccination with full-length or truncated Neu induces protective immunity against the development of spontaneous mammary tumors in HER-2/neu transgenic mice , 2000, Gene Therapy.

[59]  L. Presta,et al.  Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets , 2000, Nature Medicine.

[60]  I. Weissman,et al.  In vivo natural killer cell activities revealed by natural killer cell-deficient mice. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[61]  R. Zinkernagel,et al.  Immunotherapy with Dendritic Cells Directed against Tumor Antigens Shared with Normal Host Cells Results in Severe Autoimmune Disease , 2000, The Journal of experimental medicine.

[62]  M. Campiglio,et al.  Role of HER2 gene overexpression in breast carcinoma , 2000, Journal of cellular physiology.

[63]  S. Eccles,et al.  Cell biology of lymphatic metastasis. The potential role of c-erbB oncogene signalling. , 2000, Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer.

[64]  A. Sckell,et al.  Targeting HER‐2/neu for active‐specific immunotherapy in a mouse model of spontaneous breast cancer , 1999, International journal of cancer.

[65]  N. Robert,et al.  Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[66]  Philip Smith,et al.  Effect of c‐erbB2 and estrogen receptor status on survival of women with primary breast cancer treated with adjuvant cyclophosphamide/methotrexate/fluorouracil , 1999, International journal of cancer.

[67]  Y. Yarden,et al.  The C‐terminus of the kinase‐defective neuregulin receptor ErbB‐3 confers mitogenic superiority and dictates endocytic routing , 1999, The EMBO journal.

[68]  Monilola A. Olayioye,et al.  NDF/heregulin-induced cell cycle changes and apoptosis in breast tumour cells: role of PI3 kinase and p38 MAP kinase pathways , 1999, Oncogene.

[69]  P. Lollini,et al.  Cytokine gene therapy: hopes and pitfalls. , 1999, Annals of oncology : official journal of the European Society for Medical Oncology.

[70]  L. Esserman,et al.  Vaccination with the extracellular domain of p185neu prevents mammary tumor development in neu transgenic mice , 1999, Cancer Immunology, Immunotherapy.

[71]  S. Ménard,et al.  Target molecules for immunotherapy of inflammatory breast carcinomas. , 1998, European journal of cancer.

[72]  Mike Clarke,et al.  Polychemotherapy for early breast cancer: an overview of the randomised trials , 1998, The Lancet.

[73]  B Fisher,et al.  erbB-2 and response to doxorubicin in patients with axillary lymph node-positive, hormone receptor-negative breast cancer. , 1998, Journal of the National Cancer Institute.

[74]  D A Berry,et al.  erbB-2, p53, and efficacy of adjuvant therapy in lymph node-positive breast cancer. , 1998, Journal of the National Cancer Institute.

[75]  S. Ménard,et al.  Increased expression of c-erbB-2 in hormone-dependent breast cancer cells inhibits cell growth and induces differentiation , 1998, Oncogene.

[76]  Mike Clarke,et al.  Tamoxifen for early breast cancer: an overview of the randomised trials , 1998, The Lancet.

[77]  E. Wagner,et al.  A strain‐independent postnatal neurodegeneration in mice lacking the EGF receptor , 1998, The EMBO journal.

[78]  S. Ménard,et al.  High-titer HER-2/neu protein-specific antibody can be detected in patients with early-stage breast cancer. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[79]  D. Slamon,et al.  HER-2/neu gene amplification characterized by fluorescence in situ hybridization: poor prognosis in node-negative breast carcinomas. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[80]  P Signorelli,et al.  Antitumor efficacy of adenocarcinoma cells engineered to produce interleukin 12 (IL-12) or other cytokines compared with exogenous IL-12. , 1997, Journal of the National Cancer Institute.

[81]  N. Hynes,et al.  ErbB‐2, the preferred heterodimerization partner of all ErbB receptors, is a mediator of lateral signaling , 1997, The EMBO journal.

[82]  M. Cheever,et al.  HER-2/neu protein: a target for antigen-specific immunotherapy of human cancer. , 1997, Advances in cancer research.

[83]  M. Miloso,et al.  Post-transcriptional Control Regulates Transforming Growth Factor α in the Human Carcinoma KB Cell Line* , 1996, The Journal of Biological Chemistry.

[84]  M. Campiglio,et al.  Laminin activates the p185HER2 oncoprotein and mediates growth inhibition of breast carcinoma cells. , 1996, British Journal of Cancer.

[85]  Y. Yarden,et al.  A hierarchical network of interreceptor interactions determines signal transduction by Neu differentiation factor/neuregulin and epidermal growth factor , 1996, Molecular and cellular biology.

[86]  Y. Yarden,et al.  ErbB‐2 is a common auxiliary subunit of NDF and EGF receptors: implications for breast cancer. , 1996, The EMBO journal.

[87]  L. Zitvogel,et al.  Therapy of murine tumors with tumor peptide-pulsed dendritic cells: dependence on T cells, B7 costimulation, and T helper cell 1-associated cytokines , 1996, The Journal of experimental medicine.

[88]  S. Ménard,et al.  Macrophage infiltrate and prognosis in c-erbB-2-overexpressing breast carcinomas. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[89]  V. Jordan.  Antiestrogens and the reduction in circulating cholesterol. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[90]  L. Zitvogel,et al.  Bone marrow-derived dendritic cells pulsed with synthetic tumour peptides elicit protective and therapeutic antitumour immunity , 1995, Nature Medicine.

[91]  Kuo-Fen Lee,et al.  Requirement for neuregulin receptor erbB2 in neural and cardiac development , 1995, Nature.

[92]  Rüdiger Klein,et al.  Aberrant neural and cardiac development in mice lacking the ErbB4 neuregulin receptor , 1995, Nature.

[93]  Carmen Birchmeier,et al.  Multiple essential functions of neuregulin in development , 1995, Nature.

[94]  R. Lupu,et al.  Bidirectional interactions between the estrogen receptor and the c‐erbB‐2 signaling pathways: Heregulin inhibits estrogenic effects in breast cancer cells , 1995, International journal of cancer.

[95]  K. Herrup,et al.  Targeted disruption of mouse EGF receptor: effect of genetic background on mutant phenotype. , 1995, Science.

[96]  M. Campiglio,et al.  Colocalization of the p185HER2 oncoprotein and integrin α6β4 in Calu‐3 lung carcinoma cells , 1994 .

[97]  M. Bissell,et al.  The tumor-promoting effect of wounding: a possible role for TGF-beta-induced stromal alterations. , 1994, Critical reviews in oncogenesis.

[98]  G. Plowman,et al.  Heregulin induces tyrosine phosphorylation of HER4/p180erbB4 , 1993, Nature.

[99]  L. Presta,et al.  Humanization of an anti-p185HER2 antibody for human cancer therapy. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[100]  Yosef Yarden,et al.  Isolation of the Neu HER-2 stimulatory ligand: A 44 kd glycoprotein that induces differentiation of mammary tumor cells , 1992, Cell.

[101]  S. Ménard,et al.  Prognostic significance of her‐2/neu expression in breast cancer and its relationship to other prognostic factors , 1991, International journal of cancer.

[102]  M. Kraus,et al.  Isolation and characterization of ERBB3, a third member of the ERBB/epidermal growth factor receptor family: evidence for overexpression in a subset of human mammary tumors. , 1989, Proceedings of the National Academy of Sciences of the United States of America.

[103]  E. Scanlon,et al.  The influence of surgical trauma on experimental metastasis , 1989, Cancer.

[104]  W Godolphin,et al.  Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. , 1989, Science.

[105]  A. Ullrich,et al.  p185HER2 monoclonal antibody has antiproliferative effects in vitro and sensitizes human breast tumor cells to tumor necrosis factor , 1989, Molecular and cellular biology.

[106]  C R King,et al.  erbB-2 is a potent oncogene when overexpressed in NIH/3T3 cells. , 1987, Science.

[107]  P. Seeburg,et al.  Tyrosine kinase receptor with extensive homology to EGF receptor shares chromosomal location with neu oncogene. , 1985, Science.

[108]  P. Seeburg,et al.  Human epidermal growth factor receptor cDNA sequence and aberrant expression of the amplified gene in A431 epidermoid carcinoma cells , 1984, Nature.